Leadership Team

Luc Mainville , , , Interim Chief Executive Officer

Mr. Mainville is also Chair of the board of directors of Zucara Therapeutics Inc. Previously, Mr. Mainville served as Executive Vice President for Cardiome Pharma Corp. as well as President and Chief Executive Officer of Neopharm Labs Inc. and prior to that LAB Research Inc. He has gained considerable experience throughout his career in senior management, operational and corporate finance roles, and served as a director for a number of public and private companies in the biotechnology and pharmaceutical sectors. In particular, Mr. Mainville has led in excess of 20 public company financing transactions, totaling funds raised in excess of $200 million, as well as served as Chair and Chair of the Audit Committee for a number of Boards. He served as Vice-Chairman of BioteCanada and, prior to his career in the life science industry, Mr. Mainville was a Senior Vice President and Partner at KPMG.

Tricia Symmes , , , Chief Operating Officer

Ms. Symmes serves as Chief Operating Officer of Acerus Pharmaceuticals Corporation, leading the development and execution of Acerus Pharma’s commercialization strategy, business development, and corporate communications. Ms. Symmes brings more than 17 years of experience in the pharmaceutical industry, most recently as the General Manager for Alcon Canada (A Novartis Company). Prior to joining Alcon, Ms. Symmes held roles of increasing responsibility within Novartis Canada including, Vice President Sales, and Vice President Specialty Medicines. Ms. Symmes holds an MBA from Charles Sturt University (Australia), an Honours BSc. in Kinesiology (Western University), and a post-graduate Management Diploma in Human Resources (Humber College).

Ken Yoon , , , Chief Financial Officer

Mr. Yoon serves as the Chief Financial Officer of Acerus Pharmaceuticals Corporation. He brings more than 20 years of experience in finance and building innovative companies. Previously, Mr. Yoon held the position of CFO and VP of Corporate Development and Corporate Secretary at Vive Crop Protection Inc. Prior to Vive, Mr. Yoon was Senior Associate, Investments – Advanced Life Sciences Fund with VenGrowth Asset Management Inc. He also held several positions at Ernst & Young, notably as a co-founder of a multi-disciplinary business advisory providing consulting services to growth companies in life sciences. Mr. Yoon is a Chartered Professional Accountant (CPA, CA) and holds an M.B.A. from the University of Toronto, a Law Degree from Queen’s University and a B.Sc. from the University of Western Ontario. He is also the treasurer and a Director at the Royal Canadian Institute and is a recipient of the Queen Elizabeth II Diamond Jubilee Medal for contribution to the advancement of sciences.

Dr. Nathan Bryson , , , Chief Scientific Officer

Dr. Bryson joined Acerus from Cynapsus Therapeutics where he served as Chief Scientific Officer. He brings more than 20 years of experience in pharmaceutical development, having held scientific and executive management level positions at several pharmaceutical companies including Flamel Technologies SA, Bionisis SA, and Matregen Corporation. Dr. Bryson holds a BSc in Chemistry from Auburn University and a PhD in Radiopharmaceutical Chemistry from the Massachusetts Institute of Technology (“MIT”). He performed post-doctoral research under two well-esteemed chemists, the late Dr. J. Osborn at the University Louis Pasteur (Strasbourg, France) and Dr. D. Seyferth at MIT.

Philippe Savard , , , Vice President, General Counsel and Corporate Secretary

Mr. Savard serves as Vice President, General Counsel and Corporate Secretary with responsibility for protecting the legal interests of Acerus and managing its legal affairs. Prior to joining Acerus, Mr. Savard was Director & Counsel at DRI Capital Inc., a firm which manages private equity funds that purchase royalties owed on the sales of pharmaceutical products. Prior to his time at DRI Capital, Mr. Savard worked as an associate at the law firm of Paul, Weiss, Rifkind, Wharton & Garrison LLP in Toronto, with a practice focused on transactional corporate securities, and as an associate at the law firm of Ropes & Gray LLP in New York, with a practice focused on corporate securities, mergers and acquisition and private equity. Mr. Savard holds a B. Sc. and a M. Sc. in Microbiology and Immunology from McGill University, a J.D. from the University of Toronto and a M.B.A. from the Rotman School of Management (University of Toronto).